Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.

Employees - 21890, CEO - Kirk L. Perry, Sector - Consumer Defensive, Country - US, Market Cap -

Altman ZScore(max is 10): 2.17, Piotroski Score(max is 10): 5, Working Capital: $32000000, Total Assets: $26735000000, Retained Earnings: $-70000000, EBIT: 2599000000, Total Liabilities: $16182000000, Revenue: $15408000000

AryaFin Target Price - $43.39 - Current Price $ - Analyst Target Price $